HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6

The recently published AMP trial (HVTN 703/HPTN 081 and HVTN704/HPTN 085) results have validated broad neutralising antibodies (bNAbs) as potential anti-HIV-1 agents. However, single bNAb preparations are unlikely to cope with the onslaught of existing and de novo resistance mutations, thus necessit...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshoette, Tumelo, Papathanasopoulos, Maria Antonia, Killick, Mark Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450465/
https://www.ncbi.nlm.nih.gov/pubmed/36071449
http://dx.doi.org/10.1186/s12985-022-01876-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450465/
https://www.ncbi.nlm.nih.gov/pubmed/36071449
http://dx.doi.org/10.1186/s12985-022-01876-1

Ejemplares similares